CorMedix Inc. (CRMD) stock
CRMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 15/3087% below fair value
$4.66−0.18 (-3.72%)
Close on Nov 13, 2026Market cap $363.22MP/E –Yield –
CorMedix EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
CorMedix's EPS for the twelve months ending Sep 30, 2024 was -$0.81. For fiscal 2025 it was $2.04. The highest annual figure on record is $2.04 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.04 | – |
| FY2024 | Dec 31, 2024 | -$0.30 | – |
| FY2023 | Dec 31, 2023 | -$0.91 | – |
| FY2022 | Dec 31, 2022 | -$0.74 | – |
| FY2021 | Dec 31, 2021 | -$0.75 | – |
| FY2020 | Dec 31, 2020 | -$0.77 | – |
| FY2019 | Dec 31, 2019 | -$1.80 | – |
| FY2018 | Dec 31, 2018 | -$1.51 | – |
| FY2017 | Dec 31, 2017 | -$0.60 | – |
| FY2016 | Dec 31, 2016 | -$0.65 | – |
| FY2015 | Dec 31, 2015 | -$0.58 | – |
| FY2014 | Dec 31, 2014 | -$0.96 | – |
| FY2013 | Dec 31, 2013 | -$0.69 | – |
| FY2012 | Dec 31, 2012 | -$0.30 | – |
| FY2011 | Dec 31, 2011 | -$0.58 | – |
| FY2010 | Dec 31, 2010 | -$1.15 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$0.19 | -167.9% |
| Q2 FY2026 | Jun 30, 2026 | $0.29 | -3.3% |
| Q1 FY2026 | Mar 31, 2026 | $0.43 | – |
| Q3 FY2025 | Sep 30, 2025 | $1.26 | – |
| Q2 FY2025 | Jun 30, 2025 | $0.28 | – |
| Q1 FY2025 | Mar 31, 2025 | $0.30 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.05 | – |
| Q2 FY2024 | Jun 30, 2024 | -$0.25 | – |
| Q1 FY2024 | Mar 31, 2024 | -$0.25 | – |
| Q4 FY2023 | Dec 31, 2023 | -$0.26 | – |
| Q3 FY2023 | Sep 30, 2023 | -$0.17 | – |
| Q2 FY2023 | Jun 30, 2023 | -$0.25 | – |
| Q1 FY2023 | Mar 31, 2023 | -$0.24 | – |
| Q4 FY2022 | Dec 31, 2022 | -$0.20 | – |
| Q3 FY2022 | Sep 30, 2022 | -$0.17 | – |
| Q2 FY2022 | Jun 30, 2022 | -$0.19 | – |
| Q1 FY2022 | Mar 31, 2022 | -$0.18 | – |
| Q4 FY2021 | Dec 31, 2021 | -$0.20 | – |
| Q3 FY2021 | Sep 30, 2021 | -$0.22 | – |
| Q2 FY2021 | Jun 30, 2021 | -$0.12 | – |
| Q1 FY2021 | Mar 31, 2021 | -$0.20 | – |
| Q3 FY2020 | Sep 30, 2020 | -$0.22 | – |
| Q2 FY2020 | Jun 30, 2020 | -$0.14 | – |
| Q1 FY2020 | Mar 31, 2020 | -$0.21 | – |
| Q4 FY2019 | Dec 31, 2019 | -$0.21 | -310.0% |
| Q3 FY2019 | Sep 30, 2019 | -$1.35 | – |
| Q2 FY2019 | Jun 30, 2019 | -$0.03 | – |
| Q1 FY2019 | Mar 31, 2019 | -$0.22 | – |
| Q4 FY2018 | Dec 31, 2018 | $0.10 | – |
| Q3 FY2018 | Sep 30, 2018 | -$0.54 | – |
| Q2 FY2018 | Jun 30, 2018 | -$0.52 | – |
| Q1 FY2018 | Mar 31, 2018 | -$0.68 | – |
| Q4 FY2017 | Dec 31, 2017 | -$0.15 | – |
| Q3 FY2017 | Sep 30, 2017 | -$0.17 | – |
| Q2 FY2017 | Jun 30, 2017 | -$0.10 | – |
| Q1 FY2017 | Mar 31, 2017 | -$0.19 | – |
| Q4 FY2016 | Dec 31, 2016 | -$0.16 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?